Exploratory Study of XL765 (SAR245409) or XL147 (SAR245408) in Subjects With Recurrent Glioblastoma Who Are Candidates for Surgical Resection

NCT ID: NCT01240460

Last Updated: 2012-07-27

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 40 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2011-01-31
• Study Completion Date: 2012-06-30

Brief Summary

The purpose of this study is to measure what effect the study drug XL765 (SAR245409) or the study drug XL147 (SAR245408) has on tumor tissue in subjects with recurrent glioblastoma (GB) who are candidates for surgical resection. XL765 (SAR245409) and XL147 (SAR245408), the two investigational agents examined in this study, XL147 (SAR245408) is a potent inhibitor of PI3 Kinase (PI3K) and XL765 (SAR245409) is a dual PI3K and mTOR inhibitor. In preclinical studies, inactivation of PI3K has been shown to inhibit growth and induce apoptosis (programmed cell death) in tumor cells.

Conditions

Glioblastoma; Astrocytoma, Grade IV

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

1

Twice-daily dosing (every 12 hours) XL765

Group Type: EXPERIMENTAL

XL765 (SAR245409)

Intervention Type: DRUG

Supplied as 10-mg and/or 50-mg capsules

2

Once-daily dosing XL147

Group Type: EXPERIMENTAL

XL147 (SAR245408)

Intervention Type: DRUG

Supplied as 100-mg, 150-mg and/or 200-mg tablets

3

Once-daily dosing XL765

Group Type: EXPERIMENTAL

XL765 (SAR245409)

Intervention Type: DRUG

Supplied as 10-mg and/or 50-mg capsules

Interventions

XL765 (SAR245409)

Supplied as 10-mg and/or 50-mg capsules

Intervention Type: DRUG

XL147 (SAR245408)

Supplied as 100-mg, 150-mg and/or 200-mg tablets

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. The subject has histologically confirmed diagnosis of primary GB for which the subject has received prior treatment, including radiation and/or chemotherapy, and will be undergoing a second surgical resection.

2. The subject has available archival tumor tissue from the time of initial diagnosis of GB that is designated for central laboratory analysis.

3. The subject is ≥ 18 years old.

4. The subject has a Karnofsky performance status (KPS) ≥ 60%.

5. The subject has adequate organ and marrow function.

6. The subject has adequate fasting plasma glucose levels and glycosylated hemoglobin levels.

7. The subject is capable of understanding and complying with the protocol requirements and has signed the informed consent document.

8. Sexually active subjects (men and women) must agree to use medically-accepted barrier methods of contraception during the course of the study and for 3 months after the last dose of study drug, even if oral contraceptives are also used. All subjects of reproductive potential must agree to use both a barrier method and a second method of birth control.

9. Women of childbearing potential must have a negative pregnancy test at screening.

Exclusion Criteria

1. The subject has confirmed secondary GB (ie, had a pathology-confirmed lower-grade glioma that subsequently recurred as a higher grade glioma).

2. The subject's tumor has a predominance of WHO Grade IV oligoastrocytoma.

3. The subject has received radiation therapy for GB within 12 weeks (≤ 84 days) before their first dose of study drug treatment.

4. The subject has received specific types of anticancer therapy (should be discussed with the treating physician)

5. The subject has not recovered to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 Grade ≤ 1 from AEs due to surgery, radiation, antineoplastic agents, investigational drugs, or other medications that were administered before screening (except Grade 2 alopecia and Grade 2 lymphocytopenia).

6. The subject is receiving > 1 mg/day warfarin (or equivalent of other coumarin derivatives) and is unable to switch to low molecular weight heparin within 14 days before the first dose of study drug.

7. The subject is receiving enzyme-inducing anti-epileptic agents (EIAED; eg, carbamazepine, phenytoin, phenobarbital, or primidone) or valproic acid and is unable to convert to EIAED anti-seizure agents within 14 days before the first dose of study drug.

8. The subject has uncontrolled intercurrent illness including, but not limited to:

• Ongoing or active infection
• Hypertension (consistent blood pressure readings of > 140 mmHg systolic or > 100 mmHg diastolic) despite optimal treatment
• Significant cardiac arrhythmias, or a recent history of serious disease, such as either symptomatic congestive heart failure or unstable angina pectoris within 3 months, or the following events within 6 months: myocardial infarction, stroke, or transient ischemic attack.
• Inherited or acquired bleeding diathesis

9. The subject has a baseline corrected QT interval (QTc) > 460 ms.

10. The subject is unable to undergo repeated magnetic resonance imaging (MRI) scans for any reason (eg, cardiac pacemaker or ferromagnetic metal implants).

11. The subject is known to be positive for the human immunodeficiency virus (HIV). Note: HIV testing is not required for eligibility.

12. The subject has impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of study treatment (eg, ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection).

13. The subject is pregnant or breastfeeding.

14. The subject has a previously identified allergy or hypersensitivity to components of the study treatment formulation.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Sanofi

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Clinical Sciences & Operations

Role: STUDY_DIRECTOR

Sanofi

Locations

Investigational Site Number 840001

Los Angeles, California, United States

Investigational Site Number 840003

San Francisco, California, United States

Investigational Site Number 840004

Boston, Massachusetts, United States

Investigational Site Number 840002

New York, New York, United States

Countries

United States

Other Identifiers

XL765-202

Identifier Type: OTHER

Identifier Source: secondary_id

TED11605

Identifier Type: -

Identifier Source: org_study_id